Introduction
Indoramin (3-[2-(4-benzamidopiperid-1-yl)ethyl] indole) has been shown in animal experiments to combine competitive a-adrenoceptor blocking properties with cardioinhibitory, local anaesthetic, antihistamine and anti-5-hydroxytryptamine activity (Alps et al., 1972; Collis and Alps, 1973) . Its competitive a-adrenoceptor blocking activity has been confirmed in studies of human isolated smooth muscle strips (Variava and Turner, 1973) . Royds, Coltart and Lockhart (1972) showed that in healthy volunteers a single oral dose produced a significant fall in blood pressure when compared with placebo, and that after intravenous infusion of indoramin the pressure response to noradrenaline showed a parallel time-related shift to the right. Indoramin also produced a dose-dependent reduction in histamineinduced skin weals, but did not influence critical flicker frequency in doses which had a-adrenoceptor blocking and antihistamine activity. Boakes, Prichard and Teoh (1972) found considerable positional falls in blood pressure after intravenous and oral dosing.
Preliminary clinical studies of indoramin in patients with essential hypotension indicated that it might have a therapeutic effect in this condition (Royds, 1972) , although not all patients responded favourably in a recent study (Lewis, George and Dollery, 1973 The controlled investigation of the effects of desipramine suggest that the interaction demonstrated with guanethidine, bethanidine (Mitchell et al., 1970) and clonidine (Briant et al., 1973) in which a marked reversal of the antihypertensive effect occurs, does not arise with indoramin. In fact there was a slight additive effect with the addition of desipramine, which may be due to its c-adrenoceptor-blocking activity (McCullough and Story, 1972) .
Mitchell et al. (1970) found that the reversal of the antihypertensive effects occurred within 2 days in patients on guanethidine, and within a few hours on bethanidine and debrisoquinone, when treated with desipramine in a dose of 25 mg 8 hourly. Moreover it was seen in every patient so treated. Four or five patients on clonidine showed reversal within a week of the introduction of desipramine (Briant et al., 1973) .
It may be argued that, since there was no change in blood pressure of the patients for at least 5 weeks following withdrawal of indoramin, it is unlikely that a reversal by desipramine would be seen within 10 days. However, a prolonged period of normotension follows withdrawal of guanethidine in many cases (Dollery, 1967) although reversal with desipramine is rapid. While the possibility of a later reversal of indoramin's hypertensive effect has not been excluded, this study suggests that, where a patient with essential hypertension requires treatment with a tricyclic antidepressant drug, indoramin may be of value in the control of hypertension.
The delay in relapse of hypertension in all our patients studied after withdrawal of effective indoramin treatment illustrates an important question in the assessment of antihypertensive drugs. This effect has been reported in extensive studies with long established antihypertensive agents with different modes of action (Page and Dustan, 1962; Perry et al., 1966; Thurm and Smith, 1967) and a p-adrenoceptorblocking drug (Persson and Ulrich, 1973 (1962) suggested that this mechanism could account for their findings of a persistent effect in nine out of the twenty-seven patients whose drug treatment was discontinued in their study. Prichard and Gillam (1969) 
